{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:48:38Z","timestamp":1768002518749,"version":"3.49.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.05.009","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T17:57:12Z","timestamp":1747591032000},"page":"e656-e662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Update on Tailoring Therapy in T Cell Lymphomas"],"prefix":"10.1016","volume":"25","author":[{"given":"Christina","family":"Moe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2025.05.009_bib0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"10168","key":"10.1016\/j.clml.2025.05.009_bib0002","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.clml.2025.05.009_bib0003","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma\u2606","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.05.009_bib0004","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.clml.2025.05.009_bib0005","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.05.009_bib0006","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.05.009_bib0007","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2022-165217","article-title":"Addition of brentuximab vedotin to gemcitabine in relapsed or refractory T-cell lymphoma: final analysis of a Lysa multicenter, phase II study. \u201cthe total trial.\u201d","volume":"140","author":"Tournilhac","year":"2022","journal-title":"Blood"},{"issue":"suppl_1","key":"10.1016\/j.clml.2025.05.009_bib0008","doi-asserted-by":"crossref","first-page":"A161","DOI":"10.1093\/ajcp\/138.suppl1.147","article-title":"EZH2 Expression is increased in neoplastic T cells as compared with reactive lymphocytes and differs in different subtypes of T-cell lymphoma","volume":"138","author":"Dhiran","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"10.1016\/j.clml.2025.05.009_bib0009","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.clml.2025.05.009_bib0010","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2025.05.009_bib0011","unstructured":"National Comprehensive Cancer Network. T-cell lymphomas (Version 1.2025). NCCN.Org. 2024. Accessed: December 29, 2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf"},{"issue":"3","key":"10.1016\/j.clml.2025.05.009_bib0012","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP Phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2025.05.009_bib0013","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2025.05.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29602","article-title":"FDA approval summary: crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"69","author":"Merino","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.05.009_bib0015","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase\u2013positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.clml.2025.05.009_bib0016","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.clml.2025.05.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27094","article-title":"Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes","volume":"65","author":"Hudson","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2025.05.009_bib0018","first-page":"5179","article-title":"Mogamulizumab monotherapy in the treatment of relapsed\/refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma patients in single-institution experience","volume":"130","author":"Murai","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.05.009_bib0019","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator\u2019s choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.clml.2025.05.009_bib0020","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/bloodadvances.2020003053","article-title":"Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study","volume":"4","author":"Yonekura","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2025.05.009_bib0021","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.009_bib0022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-136061","article-title":"AVAIL-T: a phase 2a trial of Avelumab, and Anti-PD-L1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)","volume":"136","author":"Ahearne","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.05.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.clml.2025.05.009_bib0024","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor Pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"S2","key":"10.1016\/j.clml.2025.05.009_bib0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hon.118_2629","article-title":"Developing immunoepigenetic platforms for peripheral T-cell lymphoma: leveraging a logic for Pd1\/pdl-1 inhibitors","volume":"37","author":"a","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.05.009_bib0026","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-143252","article-title":"A phase II study of Pembrolizumab in combination with Romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.009_bib0027","doi-asserted-by":"crossref","first-page":"9425","DOI":"10.1182\/blood-2022-170181","article-title":"Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL): preliminary results from the Embolden trial","volume":"140","author":"Roberts","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.clml.2025.05.009_bib0028","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/hon.3164_367","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology","volume":"41","author":"Mehta-Shah","year":"2023","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.05.009_bib0029","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3390\/cancers12082293","article-title":"Phase I\/Ib study of Tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor in patients with relapsed\/refractory T-cell lymphoma","volume":"12","author":"Huen","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"S2","key":"10.1016\/j.clml.2025.05.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/hon.56_2879","article-title":"The combination of Duvelisib and Romidepsin (dr) is highly active against relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results","volume":"39","author":"Horwitz","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.05.009_bib0031","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2021-145851","article-title":"Safety and efficacy of Tenalisib given in combination with Romidepsin in patients with relapsed\/refractory T-cell lymphoma: final results from a phase I\/II open label multi-center study","volume":"138","author":"Iyer","year":"2021","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2025.05.009_bib0032","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.05.009_bib0033","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1200\/JCO.2022.40.16_suppl.7563","article-title":"A phase I\/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma","volume":"40","author":"Kim","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.009_bib0034","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.009_bib0035","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/cas.14906","article-title":"Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma","volume":"112","author":"Kawai","year":"2021","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.clml.2025.05.009_bib0036","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit?","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.clml.2025.05.009_bib0037","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2021-154142","article-title":"Early signals of anti-tumor efficacy and safety with autologous CD5.CAR T-cells in patients with refractory\/relapsed T-cell lymphoma","volume":"138","author":"Rouce","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.05.009_bib0038","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41417-021-00295-8","article-title":"A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb","volume":"29","author":"Wu","year":"2022","journal-title":"Cancer Gene Ther"},{"issue":"14","key":"10.1016\/j.clml.2025.05.009_bib0039","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarf\u00f2","year":"2018","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.clml.2025.05.009_bib0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: the cobalt-lym study of Ctx130: a phase 1 dose escalation study of Cd70-targeted allogeneic crispr-Cas9\u2013Engineered car T cells in patients with relapsed\/refractory (r\/R) T-cell malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"Hemasphere"},{"issue":"8_suppl","key":"10.1016\/j.clml.2025.05.009_bib0041","article-title":"Abstract CT024: REDIRECT: A phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R\/R) peripheral T cell lymphoma (PTCL)","volume":"83","author":"Kim","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.clml.2025.05.009_bib0042","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2016.49","article-title":"Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance","volume":"30","author":"Spinner","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.05.009_bib0043","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood-2018-07-865527","article-title":"Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.009_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.789891","article-title":"Venetoclax shows low therapeutic activity in BCL2-positive relapsed\/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi","volume":"11","author":"Ballotta","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.05.009_bib0045","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"zinzani","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2025.05.009_bib0046","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.clml.2025.05.009_bib0047","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.clml.2025.05.009_bib0048","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-sirp\u03b1 requires fc-fc\u03b3r interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.05.009_bib0049","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.05.009_bib0050","first-page":"2788","article-title":"The CXCL12\/CXCR4 pathway As a potential target of Tipifarnib: preliminary results from an open-label, phase II study in relapsed or refractory peripheral T-cell lymphoma","volume":"130","author":"Witzig","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.009_bib0051","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2021-147279","article-title":"Final results from a phase 2 study of Tipifarnib in subjects with relapsed or refractory peripheral T-cell lymphoma","volume":"138","author":"Witzig","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2025.05.009_bib0052","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood.V128.22.4164.4164","article-title":"Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas","volume":"128","author":"Delarue","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.05.009_bib0053","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/j.clml.2022.07.009","article-title":"Real-world efficacy of 5-azacytidine as salvage chemotherapy for angioimmunoblastic T-cell lymphoma","volume":"22","author":"Yoon","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.05.009_bib0054","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2022-156789","article-title":"Oral azacytidine in patients with relapsed\/refractory angioimmunoblastic T-cell lymphoma: final analysis of the Oracle Phase III study","volume":"140","author":"Dupuis","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.05.009_bib0055","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2025.05.009_bib0056","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2021-144676","article-title":"A global phase 2 study of valemetostat tosylate (Valemetostat) in patients with relapsed or refractory (R\/R) peripheral T-cell lymphoma (PTCL), including R\/R adult T-cell leukemia\/Lymphoma (ATL) - Valentine-PTCL01","volume":"138","author":"Foss","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.05.009_bib0057","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.009_bib0058","doi-asserted-by":"crossref","first-page":"9422","DOI":"10.1182\/blood-2022-165165","article-title":"A real world experience of combined treatment with Romidepsin and azacitidine in patients with peripheral T-cell lymphoma - a bridge to transplant and an effective salvage for the unfit","volume":"140","author":"Kalac","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.05.009_bib0059","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ajh.26288","article-title":"Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts","volume":"96","author":"Mehta-Shah","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.05.009_bib0060","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/10428194.2020.1861270","article-title":"Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome","volume":"62","author":"Holkova","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.clml.2025.05.009_bib0061","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3324\/haematol.2022.282220","article-title":"KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma","volume":"108","author":"Decroos","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2025.05.009_bib0062","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of Romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.05.009_bib0063","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2025.05.009_bib0064","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.clml.2025.05.009_bib0065","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971392.38916.42","article-title":"P1124: duvelisib in patients with relapsed\/refractory peripheral t-cell lymphoma from the phase 2 primo trial expansion phase: outcomes by Baseline histology","volume":"7","author":"Mehta-Shah","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"10.1016\/j.clml.2025.05.009_bib0066","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2023-179304","article-title":"Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.05.009_bib0067","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.05.009_bib0068","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2025.05.009_bib0069","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood-2024-206053","article-title":"Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed\/refractory cytotoxic lymphomas: dose escalation and optimization","volume":"144","author":"Zain","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T03:20:47Z","timestamp":1755746447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025001715"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Update on Tailoring Therapy in T Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}